Within two to four weeks we find potential targets/biomarker candidates or do a detailed target/biomarker assessment. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll contact you to discuss next steps.

Use our platform to find novel target/biomarker candidates or do detailed target/biomarker assessment yourselves. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll set up a demo to show you!

Please contact me to discuss:

Subscription to Euretos AI Platform
Euretos consulting service
Direct access to Euretos API

Euretos Announces the Addition of Leland Johnson as Business Development Director for the US East Coast and Eastern Canada

Tuesday 13 March 2018

Boston, MA and Zoetermeer, NL [March 13, 2018]

Euretos, the leader in the area of in silico discovery and validation of targets and biomarkers, announces the addition of Leland Johnson to the sales team. Based in Boston, Massachusetts, Mr. Johnson will represent Euretos for the East Coast of the United States and the Eastern Provinces of Canada.

Mr. Johnson brings knowledge and experience in the biotech and pharmaceutical industry through his years as a chemist and later as an entrepreneur in the biotechnology services industry. Prior to Euretos, Leland worked with WuXi AppTec in the area of Lab Testing Services, and before WuXi, he had his own consulting company, Conditas Biotechnology Group.

“Leland is joining Euretos at an important time in the company’s development”, says Arie Baak, Co-founder of Euretos. “We have seen significant growth of the business over the past few years and are looking to build on this success, especially by increasing our focus in the world’s most important biotech and pharma cluster. We are very happy that Leland has joined us to help achieve this ambition.”

Adds Mr. Johnson, “I am happy to join a company with such an entrepreneurial mindset; Euretos is enabling clients with valuable and actionable intelligence in the areas of target and biomarker discovery and validation based upon more than 200 widely used databases. When speaking with Arie Baak and the team, it was immediately clear to me that there is tremendous opportunity for organic growth for Euretos; especially when considering the overwhelming task of interpretation and interoperability of the mountains of internal and external data available to biotech and pharmaceutical companies.”

Leeland can be reached at:

leland.johnson [at] euretos.com


Euretos, founded in 2012 in the Netherlands, provides an AI platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their multi omics research. By integrating over 200 different public databases, the platform provides the largest single environment in which the latest multi omics data is interlinked to literature, experimental and clinical evidence. Euretos gives the power of bioinformatics in the hands of the researcher via an easy-to-use search engine and embedded analytics functions. This enables researchers to discover and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.